Allogene Therapeutics (NASDAQ:ALLO) Announces Quarterly Earnings Results

Allogene Therapeutics (NASDAQ:ALLO) posted its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Trading Up 2.6 %

Shares of ALLO stock opened at $1.94 on Friday. The stock has a 50-day moving average of $1.94 and a 200-day moving average of $2.32. The stock has a market cap of $406.76 million, a price-to-earnings ratio of -1.24 and a beta of 1.02. Allogene Therapeutics has a 1-year low of $1.32 and a 1-year high of $4.89.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research report on Friday. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a report on Friday. Finally, Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research note on Friday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.40.

Insider Activity at Allogene Therapeutics

In related news, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the sale, the insider now directly owns 250,713 shares in the company, valued at $428,719.23. This trade represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 52,710 shares of company stock worth $92,125 over the last ninety days. Insiders own 24.30% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).